Modern healthcare is being revolutionized and strengthened by artificial intelligence-based technologies that can grasp, learn, and act, whether they are used to identify novel correlations between genetic codes or to guide surgical robots. Vaccines, blood and blood components, allergic somatic cells, gene therapy, tissues, and recombinant therapeutic proteins are only a few examples of biological products, according to the US FDA. Most biologics are complicated mixes that are difficult to identify or classify, in contrast to the majority of medications, which are chemically manufactured and have a known structure. Biotechnological products, including those produced by them, have a propensity to be heat sensitive and microbial contaminated. Because of this, and in contrast to the majority of conventional pharmaceuticals, it is vital to adopt aseptic principles from the first manufacturing processes. A biologic drug (biologic) is a product that is produced from, or contains components of living organisms. Biotechnology has given rise to these organic derivatives which are sourced from humans, animals or microorganisms. As internal modifiers, biologic drugs either enhanced or inhibit biological processes that are part of the key mechanisms of action for critical pathways in healing. The study specifically focuses on the three newest applications of AI-ML in healthcare: AI-ML driven discovery and process development, clinical trials, and patient care. According to the research, companies have highly benefited from the use of AI-ML in health industries i.e. in Pharmaceuticals, Biotechnology, Clinical Trials and Digital Health by automating target identification and thus accelerating the drug discovery lifecycle. We finally anticipate potential recent interventions of AI-ML in several steps of the biological landscape, focusing on clinical trials and clinical research aspects. In this context, artificial intelligence (AI), and especially machine learning (ML), have great potential to accelerate and improve the optimization of protein properties, increasing their activity and safety as well as reducing their development time and manufacturing along with clinical trial costs.

Modern healthcare is being revolutionized and strengthened by artificial intelligence-based technologies that can grasp, learn, and act, whether they are used to identify novel correlations between genetic codes or to guide surgical robots. Vaccines, blood and blood components, allergic somatic cells, gene therapy, tissues, and recombinant therapeutic proteins are only a few examples of biological products, according to the US FDA. Most biologics are complicated mixes that are difficult to identify or classify, in contrast to the majority of medications, which are chemically manufactured and have a known structure. Biotechnological products, including those produced by them, have a propensity to be heat sensitive and microbial contaminated. Because of this, and in contrast to the majority of conventional pharmaceuticals, it is vital to adopt aseptic principles from the first manufacturing processes. A biologic drug (biologic) is a product that is produced from, or contains components of living organisms. Biotechnology has given rise to these organic derivatives which are sourced from humans, animals or microorganisms. As internal modifiers, biologic drugs either enhanced or inhibit biological processes that are part of the key mechanisms of action for critical pathways in healing. The study specifically focuses on the three newest applications of AI-ML in healthcare: AI-ML driven discovery and process development, clinical trials, and patient care. According to the research, companies have highly benefited from the use of AI-ML in health industries i.e. in Pharmaceuticals, Biotechnology, Clinical Trials and Digital Health by automating target identification and thus accelerating the drug discovery lifecycle. We finally anticipate potential recent interventions of AI-ML in several steps of the biological landscape, focusing on clinical trials and clinical research aspects. In this context, artificial intelligence (AI), and especially machine learning (ML), have great potential to accelerate and improve the optimization of protein properties, increasing their activity and safety as well as reducing their development time and manufacturing along with clinical trial costs.